August 6th 2025
Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Bridging the Digital Divide of Rural Cancer Care With Telehealth
Defining Value in Oncology Pharmacy: Insights on Care and Costs
IVBM Chair Summarizes Key Takeaways on Value-Based Oncology Care
Incorporating Discussions of Cannabis Use Into Oncology Care Visits
From Policy to Practice: NCCN Summit Explores Equity in the Cancer Workforce